Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06568172
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- M D Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Texas: - Site 22 — Austin, Texas
- Site 1 — Houston, Texas
- Site 18 — Plano, Texas
- Site 17 — Sugarland, Texas
- Site 15 — Tyler, Texas
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Texas: - GSK Investigational Site — Fort Worth, Texas
Phase 3 Recruiting Industry
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…
Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Texas: - Research Site — Dallas, Texas
- Research Site — Fort Worth, Texas
- Research Site — Houston, Texas
- Research Site — Tyler, Texas
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- Oncology Consultants — Houston, Texas
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- M D Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
- MD Anderson League City — League City, Texas
- MD Anderson in Sugar Land — Sugar Land, Texas
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Texas: - Texas Oncology - DFW ( Site 8005) — Fort Worth, Texas
- Texas Oncology - Northeast Texas ( Site 8002) — Tyler, Texas
Phase 3 Recruiting Industry
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn ab…
Sponsor: Rakuten Medical, Inc.
NCT ID: NCT06699212
Sites in Texas: - University of Texas, MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- MD Anderson in The Woodlands — Conroe, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- University of Texas Medical Branch — Galveston, Texas
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
- Local Institution - 2127 — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
- Local Institution - 2146 — Kingwood, Texas
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Texas: - Mary Crowley Cancer Research Center — Dallas, Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- University of Texas Southwestern — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- START San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Texas: - Research Site 135 — Austin, Texas
- Research Site 120 — Dallas, Texas
Phase 2 Recruiting Industry
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…
Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in Texas: - UT Health San Antonio MD Anderson Cancer Center — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Texas: - The University of Texas, MD Anderson Cancer Center — Houston, Texas
- UT Health Mays Cancer Center — San Antonio, Texas
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology, P.A. — Dallas, Texas
- Texas Oncology Gulf Coast — Pearland, Texas
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - DFW — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Texas: - USA13-0 — Anderson, Texas
- USA12-0 — Houston, Texas
Phase 2 Recruiting Industry
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receiv…
Sponsor: EpicentRx, Inc.
NCT ID: NCT05966194
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Texas: - NEXT Oncology — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
- START Center for Cancer Research — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Texas: - The University of Texas MD Anderson Cancer Center (site 127) — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Texas: - Clinical Trial Site — Houston, Texas
- Clinical Trial Site — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Texas: - Oncology Consultants, P.A. — Houston, Texas
- The University of Texas M. D. Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Texas: - NEXT Oncology - Dallas — Dallas, Texas
- START San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Texas: - Houston Methodist Hospital — Houston, Texas